The aims of this study were to determine if SPARC and FOXP3 expression levels are associated with CRC stage, disease outcome and long-term cancer-specific survival in stage II and III CRC and to compared the prognostic value of these two markers against the known prognostic CRC markers CD8 and CD45RO. The gene discussed is CD8A; the disease is colorectal carcinoma.